Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Beike Biotech Applies for China Use of Stem Cells in Lupus Patients

publication date: Jul 14, 2014
Beike Biotechnology filed with the CFDA for approval to use human umbilical cord (UC) derived mesenchymal stem cells (MSCs) to treat Systemic Lupus Erythamatosus (SLE). Beike based the request on a single-arm, 40-patient test of the treatment in patients with active, refractory SLE. The UC-derived MSCs were well-tolerated and, according to the company, provided a clinical benefit to the patients. Beike, based in Shenzhen, focuses on stem cell treatments. More details.....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital